Barinthus Biotherapeutics plc (BRNS)
NASDAQ: BRNS · Real-Time Price · USD
0.6250
+0.0450 (7.76%)
Feb 20, 2026, 4:00 PM EST - Market closed
Barinthus Biotherapeutics Revenue
In the year 2024, Barinthus Biotherapeutics had annual revenue of $14.97M with 1,766.46% growth.
Revenue (ttm)
$14.97M
Revenue Growth
+1,766.46%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
105
Market Cap
25.52M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14.97M | 14.17M | 1,766.46% |
| Dec 31, 2023 | 802.00K | -43.90M | -98.21% |
| Dec 31, 2022 | 44.70M | 44.44M | 16,580.22% |
| Dec 31, 2021 | 268.00K | -4.55M | -94.44% |
| Dec 31, 2020 | 4.82M | -2.02M | -29.57% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Neuphoria Therapeutics | 14.99M |
| Marker Therapeutics | 4.69M |
| IGC Pharma | 1.11M |
| Vistagen Therapeutics | 789.00K |
| Rallybio | 674.00K |
| Exicure | 500.00K |
| Daré Bioscience | -57.13K |
BRNS News
- 4 months ago - ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Therapeutics - PRNewsWire
- 5 months ago - BARINTHUS BIOTHERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNS - Business Wire
- 5 months ago - Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases - GlobeNewsWire
- 9 months ago - Barinthus Biotherapeutics' CEO Bill Enright to Present at the Investor Summit Virtual on June 10, 2025 - Accesswire
- 1 year ago - Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments - GlobeNewsWire
- 1 year ago - Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11 - Accesswire
- 1 year ago - Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update - GlobeNewsWire
- 1 year ago - Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer - GlobeNewsWire